ATRC vs. CSII, SILK, ATRI, LUNG, INO, ITGR, IART, ATEC, SRDX, and OFIX
Should you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Cardiovascular Systems (CSII), Silk Road Medical (SILK), Atrion (ATRI), Pulmonx (LUNG), Inovio Pharmaceuticals (INO), Integer (ITGR), Integra LifeSciences (IART), Alphatec (ATEC), Surmodics (SRDX), and Orthofix Medical (OFIX). These companies are all part of the "medical" sector.
AtriCure (NASDAQ:ATRC) and Cardiovascular Systems (NASDAQ:CSII) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.
In the previous week, AtriCure had 3 more articles in the media than Cardiovascular Systems. MarketBeat recorded 3 mentions for AtriCure and 0 mentions for Cardiovascular Systems. AtriCure's average media sentiment score of 1.24 beat Cardiovascular Systems' score of -0.11 indicating that AtriCure is being referred to more favorably in the media.
AtriCure currently has a consensus target price of $49.78, suggesting a potential upside of 122.02%. Given AtriCure's higher probable upside, equities analysts clearly believe AtriCure is more favorable than Cardiovascular Systems.
AtriCure received 129 more outperform votes than Cardiovascular Systems when rated by MarketBeat users. Likewise, 68.98% of users gave AtriCure an outperform vote while only 61.93% of users gave Cardiovascular Systems an outperform vote.
AtriCure has higher revenue and earnings than Cardiovascular Systems. AtriCure is trading at a lower price-to-earnings ratio than Cardiovascular Systems, indicating that it is currently the more affordable of the two stocks.
99.1% of AtriCure shares are owned by institutional investors. Comparatively, 86.6% of Cardiovascular Systems shares are owned by institutional investors. 3.2% of AtriCure shares are owned by insiders. Comparatively, 3.8% of Cardiovascular Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
AtriCure has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Cardiovascular Systems has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
AtriCure has a net margin of -8.98% compared to Cardiovascular Systems' net margin of -15.79%. AtriCure's return on equity of -7.85% beat Cardiovascular Systems' return on equity.
Summary
AtriCure beats Cardiovascular Systems on 14 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AtriCure Competitors List
Related Companies and Tools
